CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Phase 3REZPEGNeutral
AI Analysis

Summary

Nektar Therapeutics outlined its Phase 3 timeline for REZPEG with mid-2028 data expected and a BLA submission planned for 2029.

Clinical Trial Data

Phase

Phase 3

Importance:6/10
Sentiment:
0.00
Phase 3BLA FilingREZPEGClinical Timeline
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on August 14, 2026 3:27 AM

Read Original